ArticleCureus2025
Patients' Concerns for Hormone-Replacement Therapy for Menopause.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile most women experience significant perimenopausal symptoms, only a percentage utilize hormone-replacement therapy (HRT). Despite the publicized risks, HRT provides benefits beyond perimenopausal symptom improvement, including decreased risk of cardiovascular disease, stroke, osteoporosis, and affective disorders, and quality of life.
methodsSubjects were recruited randomly in four clinics. The survey data is uploaded to a survey platform. Data were analyzed to identify reasons for HRT refusal, and to see what associations exist between menopause severity and use of HRT.
results71 subjects in total completed the survey. 25 (35%) have never used HRT, and 46 (65%) have used it before. 17 (24%) individuals stated that concerns regarding cancer were central to decision-making on whether they opted to utilize HRT. Possible cancer risk was the most common concern (34, 48%) among the entire study population. The difference between the two groups was not significant regarding specific concerns and reasons as to why they did or did not receive this treatment for menopause. For the Menopause Rating Scale (MRS), the non-HRT group (Group 1) mean was 7.79, and the HRT group (Group 2) mean was 15.07. This difference was significant (two-tailed p = 0.0009). Conclusions: Findings from this study show there is still a large proportion of women concerned about risks of HRT especially regarding cancer. Future studies aimed at addressing significance in HRT's effect on osteoporosis, cardiovascular disease, and more that impact the morbidity and mortality of menopausal women could be vital to finding a unified stance on this topic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.